These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34526363)

  • 1. Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma.
    Chen S; Xie Y; Cai Y; Hu H; He M; Liu L; Liao C; Wang Y; Wang J; Ren X; Zeng Q; Peng H; Shen S; Li S; Li D; Lai J; Peng B; Ren J; Kuang M; Peng S
    Clin Cancer Res; 2022 May; 28(9):1896-1910. PubMed ID: 34526363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis.
    Bao X; Li Q; Chen J; Chen D; Ye C; Dai X; Wang Y; Li X; Rong X; Cheng F; Jiang M; Zhu Z; Ding Y; Sun R; Liu C; Huang L; Jin Y; Li B; Lu J; Wu W; Guo Y; Fu W; Langley SR; Tano V; Fang W; Guo T; Sheng J; Zhao P; Ruan J
    Cancer Immunol Res; 2022 Jul; 10(7):811-828. PubMed ID: 35604302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
    Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
    Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
    Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
    Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
    Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma.
    Sulpice L; Rayar M; Turlin B; Boucher E; Bellaud P; Desille M; Meunier B; Clément B; Boudjema K; Coulouarn C
    J Surg Res; 2014 Nov; 192(1):117-23. PubMed ID: 24909871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.
    Kim YH; Hong EK; Kong SY; Han SS; Kim SH; Rhee JK; Hwang SK; Park SJ; Kim TM
    Oncotarget; 2016 Apr; 7(17):23825-36. PubMed ID: 27009864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
    Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
    Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ; Hewitt DB; Pawlik TM
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features.
    Chen Y; Liu X; Huang L; Chen L; Wang B
    Expert Rev Mol Diagn; 2023 May; 23(5):445-456. PubMed ID: 37078255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma.
    Jiang H; Gao B; Meng Z; Wang Y; Jiao T; Li J; Li X; Cao Y; Zhang X; Li C; Lu S
    J Transl Med; 2024 Oct; 22(1):948. PubMed ID: 39427165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.